Statistical modelling issues in the RODIN study

Haemophilia

Volumn 20, Issue 4, 2014, Pages

  Moorehead, P C ^a  

^a New Janeway Childrens Health and Rehabilitation Centre   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8 INHIBITOR; RECOMBINANT BLOOD CLOTTING FACTOR 8; ALLOANTIBODY; ANTIBODY; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING INHIBITOR; RECOMBINANT PROTEIN;

CLINICAL STUDY; DRUG EFFECT; HEMOPHILIA A; HUMAN; LETTER; LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; RISK FACTOR; STATISTICAL MODEL; STATISTICAL SIGNIFICANCE; ANIMAL; BLOOD; IMMUNOLOGY; MALE;

ANIMALS; ANTIBODIES; BLOOD COAGULATION FACTOR INHIBITORS; FACTOR VIII; HEMOPHILIA A; HUMANS; ISOANTIBODIES; MALE; RECOMBINANT PROTEINS;

EID: 84904743759     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12458     Document Type: Letter

References (6)

1. Gouw SC, van der Bom JG, Ljung R, et al. Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med 2013; 368: 231-9.
2. Kessler CM, Iorio A. The Rodin (Research Of Determinants of INhibitor Development among PUPs with haemophilia) study: the clinical conundrum from the perspective of haemophilia treaters. Haemophilia 2013; 19: 351-4.
3. Van der Bom JG, Gouw SC, Rosendaal FR. Second-generation recombinant factor VIII and inhibitor risk: interpretation of RODIN study findings and implications for patients with haemophilia A. Haemophilia 2014; 20: e171-4.
4. Tu Y-K, Gunnell D, Gilthorpe MS. Simpson's Paradox, Lord's Paradox, and Suppression Effects are the same phenomenon-the reversal paradox. Emerg Themes Epidemiol 2008; 5: 2.
5. Babyak MA. What you see may not be what you get: a brief, nontechnical introduction to overfitting in regression-type models. Psychosom Med 2004; 66: 411-21.
6. Shmueli G. To explain or to predict? Stat Sci 2010; 25: 289-310.